Esperion Therapeutics, Inc.
Simbols: ESPR
NASDAQ
2.05
USDTirgus cena šodien
-0.9875
P/E koeficients
0.0209
PEG koeficients
349.36M
MRK Cap
- 0.00%
DIV ienesīgums
Esperion Therapeutics, Inc. (ESPR) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2002 | 2001 | 2000 | 1999 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 497.89 | 82.2 | 124.8 | 208.9 | |||||||||||||||||
balance-sheet.row.short-term-investments | 17.43 | 0 | 42.1 | 50.4 | |||||||||||||||||
balance-sheet.row.net-receivables | 168.33 | 48.5 | 33.7 | 22.9 | |||||||||||||||||
balance-sheet.row.inventory | 202.09 | 65.6 | 35.2 | 34.4 | |||||||||||||||||
balance-sheet.row.other-current-assets | 20.89 | 4.7 | 9.9 | 62.8 | |||||||||||||||||
balance-sheet.row.total-current-assets | 902.02 | 201.1 | 246.7 | 329 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 11.3 | 4.7 | 1.2 | 2.6 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.intangible-assets | 0.22 | 0.1 | 0.1 | 0.1 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0.22 | 0.1 | 0.1 | 0.1 | |||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 42.1 | 50.4 | |||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | -50.4 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | -3.72 | 0 | -42.1 | 50 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 11.52 | 4.7 | 1.3 | 52.6 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 913.55 | 205.8 | 247.9 | 381.6 | |||||||||||||||||
balance-sheet.row.account-payables | 99.56 | 31.7 | 23 | 17.6 | |||||||||||||||||
balance-sheet.row.short-term-debt | 38.29 | 36.4 | 0.4 | 1.4 | |||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 1288.3 | 501.5 | 260.6 | 258.8 | |||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0.6 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 285.83 | 62.7 | 65.4 | 48.7 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 1983.59 | 504.6 | 479.4 | 505.2 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 9.46 | 3 | 1 | 1.9 | |||||||||||||||||
balance-sheet.row.total-liab | 2480.18 | 660.8 | 571.7 | 578.5 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0.42 | 0.1 | 0.1 | 0.1 | |||||||||||||||||
balance-sheet.row.retained-earnings | -5895.67 | -1549.3 | -1340 | -1106.4 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 3256.52 | 1094.2 | -0.1 | 0 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | -2638.73 | -455 | -1340 | -1106.4 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | -158.55 | 205.8 | -768.3 | -527.8 | |||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-equity | -2638.73 | -455 | -1340 | -1106.4 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | -158.55 | - | - | - | |||||||||||||||||
Total Investments | 17.43 | 0 | 84.2 | 100.9 | |||||||||||||||||
balance-sheet.row.total-debt | 1329.61 | 540.9 | 260.9 | 260.2 | |||||||||||||||||
balance-sheet.row.net-debt | 849.15 | 458.7 | 136.2 | 51.3 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2002 | 2001 | 2000 | 1999 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -209.25 | -209.2 | -233.7 | -269.1 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0.16 | 0.2 | 0.5 | 0.6 | |||||||||||||||||
cash-flows.row.deferred-income-tax | -17.56 | 36.5 | 0 | -2.6 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 11.96 | 12 | 15.2 | 24.3 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 13.68 | 13.7 | -3.4 | -52.5 | |||||||||||||||||
cash-flows.row.account-receivables | -14.77 | -14.8 | -10.8 | -10.5 | |||||||||||||||||
cash-flows.row.inventory | -30.42 | -30.4 | -0.8 | -18.3 | |||||||||||||||||
cash-flows.row.account-payables | 8.68 | 8.7 | 5.6 | -34.1 | |||||||||||||||||
cash-flows.row.other-working-capital | 50.18 | 50.2 | 2.6 | 10.4 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 65.52 | 11.5 | 46.5 | 35.5 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -135.49 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -59.9 | -50.5 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 42.5 | 42.5 | 68 | 0 | |||||||||||||||||
cash-flows.row.other-investing-activites | 42.5 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 42.5 | 42.5 | 8.1 | -50.5 | |||||||||||||||||
cash-flows.row.debt-repayment | -15.51 | -15.5 | -58.2 | -0.8 | |||||||||||||||||
cash-flows.row.common-stock-issued | 13.52 | 66 | 90.8 | 218.7 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | -0.02 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-financing-activites | 53.81 | 0 | -50.2 | 50.3 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 50.46 | 50.5 | 32.6 | 268.2 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-change-in-cash | -42.53 | -42.5 | -134.1 | -46.1 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 480.46 | 82.2 | 124.8 | 258.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 522.99 | 124.8 | 258.9 | 305 | |||||||||||||||||
cash-flows.row.operating-cash-flow | -135.49 | -135.5 | -174.8 | -263.8 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.free-cash-flow | -135.49 | -135.5 | -174.8 | -263.8 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2002 | 2001 | 2000 | 1999 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 116.33 | 116.3 | 75.5 | 78.4 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 43.27 | 43.4 | 27 | 14.2 | |||||||||||||||||
income-statement-row.row.gross-profit | 73.06 | 72.9 | 48.5 | 64.2 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 86.11 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 29.82 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 15.6 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | 22.52 | 5.3 | 2.7 | 4 | |||||||||||||||||
income-statement-row.row.operating-expenses | 248.79 | 228.5 | 228 | 291 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 271.9 | 271.9 | 255 | 305.2 | |||||||||||||||||
income-statement-row.row.interest-income | 5.11 | 4.8 | 2.6 | 0.1 | |||||||||||||||||
income-statement-row.row.interest-expense | -0.09 | 59 | 56.8 | 46.4 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 15.6 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -53.69 | -53.7 | -54.2 | -42.4 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | 22.52 | 5.3 | 2.7 | 4 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | -53.69 | -53.7 | -54.2 | -42.4 | |||||||||||||||||
income-statement-row.row.interest-expense | -0.09 | 59 | 56.8 | 46.4 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 1.36 | 0.2 | 2.7 | 4 | |||||||||||||||||
income-statement-row.row.ebitda-caps | -154.28 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | -155.56 | -155.6 | -179.5 | -226.7 | |||||||||||||||||
income-statement-row.row.income-before-tax | -209.25 | -209.2 | -233.7 | -269.1 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 27.42 | 0 | 54.2 | 49.7 | |||||||||||||||||
income-statement-row.row.net-income | -236.75 | -209.2 | -287.8 | -318.8 |
Biežāk uzdotie jautājumi
Kas ir Esperion Therapeutics, Inc. (ESPR) kopējie aktīvi?
Esperion Therapeutics, Inc. (ESPR) kopējie aktīvi ir 205796000.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir 66219000.000.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.628.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir -1.205.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir -2.035.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir -1.337.
Kāda ir Esperion Therapeutics, Inc. (ESPR) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -209248000.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 540947000.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 228466000.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 82248000.000.